/DRMA
DRMA Stock - Dermata Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.14-0.70%
$0.01 (-0.70%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.99
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+180.4%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DRMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.12 – $2.16
TARGET (TP)$6.00
STOP LOSS$1.97
RISK/REWARD1:22.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.53
52W High$23.70
52W Low$2.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-322 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,513,242 | $-8,042,000 | $-9,674,486 | $-7,856,864 | $-3,172,853 |
| Net Income | $-12,287,461 | $-7,795,000 | $-9,610,913 | $-7,902,477 | $-3,236,530 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-80.32 | $-401.80 | $-139.20 | $-152.70 | $-932.64 |
Company Overview
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DRMABeat Rate
22%
Last 18 quarters
Avg Surprise
-501.3%
EPS vs Estimate
Beats / Misses
4/14
Last 12 quarters
Latest EPS
$-1.65
Q4 2025
EPS Surprise History
Q1 24
-303.8%
$-3.15vs$-0.78
Q2 24
-30.6%
$-7.05vs$-5.40
Q3 24
-10.3%
$-4.18vs$-3.79
Q4 24
+22.7%
$-2.04vs$-2.64
Q1 25
-110.0%
$-3.15vs$-1.50
Q2 25
-900.0%
$-4.50vs$-0.45
Q3 25
+42.8%
$-1.66vs$-2.90
Q4 25
-3.8%
$-1.65vs$-1.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $-1.59 | $-1.65 | -3.8% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-2.90 | $-1.66 | +42.8% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.45 | $-4.50 | -900.0% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-1.50 | $-3.15 | -110.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-2.64 | $-2.04 | +22.7% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-3.79 | $-4.18 | -10.3% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-5.40 | $-7.05 | -30.6% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.78 | $-3.15 | -303.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.63 | $-8.10 | -1185.7% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.92 | $-9.45 | -927.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-2.65 | $-34.03 | -1184.2% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $3.20 | $-28.79 | -999.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-3.52 | $-47.98 | -1263.1% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-5.12 | $-57.57 | -1024.4% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-6.40 | $-79.16 | -1136.9% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-5.68 | $-4.16 | +26.8% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-7.36 | $-13.76 | -87.0% | ✗ MISS |
Q3 2021 | Sep 27, 2021 | $-22.56 | $-11.20 | +50.4% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | — | $-4.43 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Latest News
Dermata Therapeutics Files For Mixed Shelf Of Up To $100M
➖ NeutralBenzinga•Nov 24, 2025, 04:23 PM
Dermata Therapeutics Terminated License Agreement With Villani Dated Mar 31, 2017, Citing Strategic Shift To OTC Skin Care; Villani Will Not Recieve Milestone, Other Payments
📉 NegativeBenzinga•Nov 18, 2025, 11:05 AM
Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate
📉 NegativeBenzinga•Nov 14, 2025, 09:07 PM
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
📈 PositiveBenzinga•Oct 2, 2025, 12:02 PM
Dermata Therapeutics To Present Phase 3 STAR-1 XYNGARI Abstract Highlighting Data In Moderate-To-Severe Acne At EADV Congress 2025
📈 PositiveBenzinga•Sep 17, 2025, 06:14 AM
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
📈 PositiveBenzinga•Sep 10, 2025, 12:09 PM
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10
➖ NeutralBenzinga•Aug 21, 2025, 04:32 PM
Frequently Asked Questions about DRMA
What is DRMA's current stock price?
Dermata Therapeutics, Inc. (DRMA) is currently trading at $2.14 per share. The stock has moved -0.70% today.
What is the analyst price target for DRMA?
The average analyst price target for DRMA is $6.00, based on 1 analyst.
What sector is Dermata Therapeutics, Inc. in?
Dermata Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DRMA's market cap?
Dermata Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does DRMA pay dividends?
No, Dermata Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
ATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
CARM
Carisma Therapeutics, Inc.
$0.05
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to DRMA for comparison